- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMED LUBLIN Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 64,32 | +0,22 % | dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion | Press Release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025
dsm-firmenich... ► Artikel lesen | |
| GENMAB | 193,95 | -0,69 % | Genmab A/S: Genmab Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial | New data showed that rinatabart sesutecan (Rina-S) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 2,962 | -2,89 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,800 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) | Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement... ► Artikel lesen | |
| VERICEL | 37,600 | -2,08 % | Canaccord Genuity reiterates Buy rating on Vericel stock with $61 target | ||
| SENSEI BIOTHERAPEUTICS | 0,310 | -0,32 % | H.C. Wainwright stuft Sensei Biotherapeutics-Aktie mit "Kaufen" ein | ||
| MUSTGROW BIOLOGICS | 0,542 | -5,90 % | MustGrow Biologics Corp.: MustGrow Announces Record Q1-2025 Results: $3.8 Million Revenue, 14.3% Gross Profit Margin, $4.4 Million in Cash and Inventory | Register/View Here: https://us02web.zoom.us/webinar/register/6217478678603/WN_h8uMVWINQsmS3HWF8K59WgPlease join/register at least 5 minutes prior to the call.Questions emailed to info@mustgrow.ca will... ► Artikel lesen | |
| BIOXCEL THERAPEUTICS | 1,360 | -100,00 % | BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders ... | DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical... ► Artikel lesen | |
| REGENXBIO | 8,300 | -1,78 % | REGENXBIO Inc.: Regenxbio Reports New Positive Functional Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne
All dose level 2 participants exceeded external natural history controls on all... ► Artikel lesen | |
| AKEBIA | 3,498 | +0,52 % | Akebia Therapeutics, Inc.: Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology | CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 6,950 | -6,08 % | Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 7,600 | -1,94 % | Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders | Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against... ► Artikel lesen | |
| REVANCE THERAPEUTICS | 3,420 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 07.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.02.2025ISIN NameCA09226M1005 BLACK... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 3,560 | +3,49 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 7,800 | -2,50 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen |
BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,002 (-0,17 %) liegt der Kurs bei 1,182 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMED-LUBLIN WYTWORNIA SUROWIC I SZCZEPIONEK SA finden Sie auf Wallstreet Online.